Treatment of relapsed central nervous system lymphoma with high-dose methotrexate

Scott R. Plotkin, Rebecca Betensky, Fred H. Hochberg, Stuart A. Grossman, Glenn J. Lesser, L. Burt Nabors, Brian Chon, Tracy T. Batchelor

Research output: Contribution to journalReview article

Abstract

Purpose: Over the past decade, high-dose methotrexate has emerged as the single most effective agent in the initial treatment of primary nervous system lymphoma. However, the majority of patients who respond initially to treatment relapse. The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma. Experimental Design: Patients with relapsed disease were eligible if they achieved a complete response to initial treatment with methotrexate-based chemotherapy or received methotrexate after gross total resection of interstitial radiation. All of the patients were retreated with a regimen containing high-dose methotrexate (≥3 g/m2). Results: Twenty-two patients with a median age of 58 years were included in the study. Overall response rates were 91% to first salvage (20 of 22 patients) and 100% to second salvage (4 of 4 patients). Median survival was 61.9 months after first relapse (95% confidence interval, 42.1-∞) and 91.9 months overall (95% confidence interval, 47.2-∞). Toxicity was primarily hematologic with 10 episodes of grade 3 or 4 toxicity during 566 cycles of chemotherapy. Conclusions: These results indicate that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to methotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.

Original languageEnglish (US)
Pages (from-to)5643-5646
Number of pages4
JournalClinical Cancer Research
Volume10
Issue number17
DOIs
StatePublished - Sep 1 2004

Fingerprint

Methotrexate
Lymphoma
Central Nervous System
Therapeutics
Confidence Intervals
Recurrence
Drug Therapy
Poisons
Nervous System
Multicenter Studies
Research Design
Retrospective Studies
Radiation
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Plotkin, S. R., Betensky, R., Hochberg, F. H., Grossman, S. A., Lesser, G. J., Nabors, L. B., ... Batchelor, T. T. (2004). Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clinical Cancer Research, 10(17), 5643-5646. https://doi.org/10.1158/1078-0432.CCR-04-0159

Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. / Plotkin, Scott R.; Betensky, Rebecca; Hochberg, Fred H.; Grossman, Stuart A.; Lesser, Glenn J.; Nabors, L. Burt; Chon, Brian; Batchelor, Tracy T.

In: Clinical Cancer Research, Vol. 10, No. 17, 01.09.2004, p. 5643-5646.

Research output: Contribution to journalReview article

Plotkin, SR, Betensky, R, Hochberg, FH, Grossman, SA, Lesser, GJ, Nabors, LB, Chon, B & Batchelor, TT 2004, 'Treatment of relapsed central nervous system lymphoma with high-dose methotrexate', Clinical Cancer Research, vol. 10, no. 17, pp. 5643-5646. https://doi.org/10.1158/1078-0432.CCR-04-0159
Plotkin, Scott R. ; Betensky, Rebecca ; Hochberg, Fred H. ; Grossman, Stuart A. ; Lesser, Glenn J. ; Nabors, L. Burt ; Chon, Brian ; Batchelor, Tracy T. / Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 17. pp. 5643-5646.
@article{76e4713e9b5947179c9f4b312d389bc9,
title = "Treatment of relapsed central nervous system lymphoma with high-dose methotrexate",
abstract = "Purpose: Over the past decade, high-dose methotrexate has emerged as the single most effective agent in the initial treatment of primary nervous system lymphoma. However, the majority of patients who respond initially to treatment relapse. The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma. Experimental Design: Patients with relapsed disease were eligible if they achieved a complete response to initial treatment with methotrexate-based chemotherapy or received methotrexate after gross total resection of interstitial radiation. All of the patients were retreated with a regimen containing high-dose methotrexate (≥3 g/m2). Results: Twenty-two patients with a median age of 58 years were included in the study. Overall response rates were 91{\%} to first salvage (20 of 22 patients) and 100{\%} to second salvage (4 of 4 patients). Median survival was 61.9 months after first relapse (95{\%} confidence interval, 42.1-∞) and 91.9 months overall (95{\%} confidence interval, 47.2-∞). Toxicity was primarily hematologic with 10 episodes of grade 3 or 4 toxicity during 566 cycles of chemotherapy. Conclusions: These results indicate that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to methotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.",
author = "Plotkin, {Scott R.} and Rebecca Betensky and Hochberg, {Fred H.} and Grossman, {Stuart A.} and Lesser, {Glenn J.} and Nabors, {L. Burt} and Brian Chon and Batchelor, {Tracy T.}",
year = "2004",
month = "9",
day = "1",
doi = "10.1158/1078-0432.CCR-04-0159",
language = "English (US)",
volume = "10",
pages = "5643--5646",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Treatment of relapsed central nervous system lymphoma with high-dose methotrexate

AU - Plotkin, Scott R.

AU - Betensky, Rebecca

AU - Hochberg, Fred H.

AU - Grossman, Stuart A.

AU - Lesser, Glenn J.

AU - Nabors, L. Burt

AU - Chon, Brian

AU - Batchelor, Tracy T.

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Purpose: Over the past decade, high-dose methotrexate has emerged as the single most effective agent in the initial treatment of primary nervous system lymphoma. However, the majority of patients who respond initially to treatment relapse. The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma. Experimental Design: Patients with relapsed disease were eligible if they achieved a complete response to initial treatment with methotrexate-based chemotherapy or received methotrexate after gross total resection of interstitial radiation. All of the patients were retreated with a regimen containing high-dose methotrexate (≥3 g/m2). Results: Twenty-two patients with a median age of 58 years were included in the study. Overall response rates were 91% to first salvage (20 of 22 patients) and 100% to second salvage (4 of 4 patients). Median survival was 61.9 months after first relapse (95% confidence interval, 42.1-∞) and 91.9 months overall (95% confidence interval, 47.2-∞). Toxicity was primarily hematologic with 10 episodes of grade 3 or 4 toxicity during 566 cycles of chemotherapy. Conclusions: These results indicate that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to methotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.

AB - Purpose: Over the past decade, high-dose methotrexate has emerged as the single most effective agent in the initial treatment of primary nervous system lymphoma. However, the majority of patients who respond initially to treatment relapse. The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma. Experimental Design: Patients with relapsed disease were eligible if they achieved a complete response to initial treatment with methotrexate-based chemotherapy or received methotrexate after gross total resection of interstitial radiation. All of the patients were retreated with a regimen containing high-dose methotrexate (≥3 g/m2). Results: Twenty-two patients with a median age of 58 years were included in the study. Overall response rates were 91% to first salvage (20 of 22 patients) and 100% to second salvage (4 of 4 patients). Median survival was 61.9 months after first relapse (95% confidence interval, 42.1-∞) and 91.9 months overall (95% confidence interval, 47.2-∞). Toxicity was primarily hematologic with 10 episodes of grade 3 or 4 toxicity during 566 cycles of chemotherapy. Conclusions: These results indicate that high-dose methotrexate remains effective for relapsed central nervous system lymphoma in patients who initially respond to methotrexate and raise the possibility of deferring more toxic salvage regimens in this select group of patients.

UR - http://www.scopus.com/inward/record.url?scp=4444269516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444269516&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-0159

DO - 10.1158/1078-0432.CCR-04-0159

M3 - Review article

C2 - 15355887

AN - SCOPUS:4444269516

VL - 10

SP - 5643

EP - 5646

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 17

ER -